FINWIRES · TerminalLIVE
FINWIRES

Emergent BioSolutions Signs $34.5 Million Manufacturing Deal With Substipharm Biologics

By

Emergent BioSolutions (EBS) said Tuesday it has signed a $34.5 million deal with Substipharm Biologics to support drug substance manufacturing for the Japanese encephalitis vaccine at its Canton, Massachusetts, facility.

As part of the agreement, Emergent said it will be the exclusive distributor of the vaccine to the US government, following potential US Food and Drug Administration regulatory clearances.

Under a master manufacturing services agreement, Emergent said it will conduct operational and regulatory inspection readiness activities for the vaccine.

Emergent shares were up 1.6% in Tuesday trading.

Price: $8.16, Change: $+0.13, Percent Change: +1.62%

Related Articles

Wire

Jade Gas Holdings Gets Mongolian Authority Approval for Coal Bed Methane Project Appraisal Report

Jade Gas Holdings (ASX:JGH) received approval from the Mineral Resources and Petroleum Authority of Mongolia for its appraisal report for the Tavantolgoi coal bed methane project, according to a Tuesday Australian bourse filing.The next stage in securing a long-term production license for the project is reserve booking, which will validate and register the company's maiden gas reserves under Mongolia's mineral and petroleum reporting standards, per the filing.The company's shares fell nearly 2% in recent trading on Tuesday but earlier hit their highest since May 2024.

ASX:JGH
Wire

Brown & Brown Q1 Adjusted Earnings, Revenue Rise

Brown & Brown (BRO) reported Q1 adjusted earnings late Monday of $1.39 per diluted share, up from $1.29 a year earlier.Analysts polled by FactSet expected $1.36.Revenue for the three months ended March 31 was $1.9 billion, up from $1.4 billion a year earlier.Analysts surveyed by FactSet expected $1.89 billion.The company's shares rose 2.8% in after-hours trading.

$BRO
Wire

Ranger Energy Services Q1 Earnings, Revenue Rise; Shares Fall After Hours

Ranger Energy Services (RNGR) reported Q1 earnings Monday of $0.12 per diluted share, up from $0.03 a year earlier.One analyst polled by FactSet expected $0.13.Revenue in the three months ended March 31 rose to $159.1 million from $135.2 million a year earlier.Three analysts surveyed by FactSet expected $156.2 million.Ranger Energy shares fell 10% in after-hours trading.

$RNGR